A pilot study of the comparative bioavailability of estradiol from two different estradiol transdermal systems: Oesclim® 50 and Systen® 50

Current Therapeutic Research

Volumn 56, Issue 10, 1995, Pages 1022-1032

  Guichard, Jean Pierre ^a   Sauron, Renée ^a   Dutertre, Jean Paul ^a   Tanner, Trevor ^b   Woodward, Alan J ^b   Dewland, Peter M ^b  

^a Laboratoires Fournier SA   (France)

^b SIMBEC RESEARCH LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; NAUSEA; NORMAL HUMAN; PHARMACEUTICS; POSTMENOPAUSE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; RASH; TRANSDERMAL DRUG ADMINISTRATION; VOLUNTEER; VOMITING;

EID: 0028802548     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0011-393X(95)85108-9     Document Type: Article

References (10)

1. Transdermal estradiol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints
2. Comparative metabolic study of percutaneous versus oral micronized 17β estradiol in replacement therapy
3. Estrogen replacement therapy
4. Biological effects of estradiol 17β in post-menopausal women Oral versus percutaneous administration
5. Pharmacokinetic considerations in the use of newer transdermal formulations
6. A methodological critic of the “ideal weight” concept
7. Reference weights Practical considerations
8. Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17β-estradiol: Comparison with conventional oral estrogens used for hormone replacement
9. Dose-dependent response of symptoms, pituitary, and bone to transdermal oestrogen in postmenopausal women